XenoPort to Present at the Wells Fargo Securities Healthcare Conference

Wells Fargo Healthcare Conference 2013

SANTA CLARA, Calif.--()--XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Wells Fargo Securities Research & Economics 2013 Healthcare Conference. The live presentation will occur at 8:15 a.m. Pacific Time (11:15 a.m. Eastern Time) on Wednesday, June 19, 2013. A replay of the presentation will also be available.

To access the live presentation via the Web, please go to www.XenoPort.com. Please connect to the Web site at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the Webcast.

A replay of the Webcast can be accessed for a minimum of one month and will be available approximately 24 hours after the live presentation.

About XenoPort

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.

To learn more about XenoPort, please visit the Web site at www.XenoPort.com.

Horizant, Regnite and XENOPORT are registered trademarks of XenoPort, Inc.

XNPT2G

Contacts

XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com

Sharing

Contacts

XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com